Marsh Barbel's Diuretic Tradition and Kidney-Stone Claims

This is the flagship claim — the one the Sanskrit classification mutrala (diuretic) and the seed's whole traditional identity are built on. It is also, once you go looking for the actual retrievable paper behind it rather than the reputation, the thinnest of the four claims examined in this Benefits leg. That thinness is worth stating precisely rather than gesturing at, because "several studies" and "one preliminary study from 1967" are very different claims, and a careful live search across every name this plant has published under turns up the second one.

Table of Contents

1. What Is Actually Being Claimed
2. One Retrievable Primary Study, From 1967
3. Old, Weak and Positive — a Third Verdict
4. The Furosemide Comparison That Could Not Be Confirmed
5. The Potassium Mechanism: Best Explanation and Main Hazard
6. Kidney Stones: a Real Study, and What It Actually Shows
7. A Second Renal Study: Cisplatin Protection
8. How Diuresis and Stone Risk Are Actually Measured
9. Drug Interactions: Reasoned From Pharmacology, Not From a Study
10. What a UTI or an Active Stone Actually Needs
11. Human Evidence: Checked, and Absent
12. Key Research Papers
13. Connections

What Is Actually Being Claimed

Three separate claims share the "good for the urinary tract" label:

1. A true diuretic effect — the plant increases urine output through some pharmacological action, independent of how much water is drunk alongside it.
2. Prevention or dissolution of kidney stones — the plant either stops stones from forming or breaks down ones that already exist.
3. Symptomatic relief of urinary burning or discomfort — a demulcent, coating effect from the seed mucilage, distinct from any pharmacological action on the kidney itself.

Claim 1 has exactly one retrievable primary study. Claim 2 has a real but narrow rodent finding that supports prevention of new mineral deposition, not dissolution of existing stones — a distinction marketing routinely erases. Claim 3 is mechanistically plausible (mucilage genuinely does coat mucous membranes) but untested here specifically, and is discussed on the parent page.

One Retrievable Primary Study, From 1967

A systematic, synonym-scoped search of PubMed — combining all four taxonomic names this plant has published under with "diuretic," "diuresis," "urine volume," "natriuretic," "urinary output," "saluretic" and "furosemide" — returns exactly one primary experimental paper: Kumari GS and Iyer GY, Preliminary studies on the diuretic effects of Hygrophila spinosa and Tribulus terrestris, published in the Indian Journal of Medical Research in July 1967. Two comprehensive reviews of the plant (2010 and 2018) also turn up in a "diuretic" search, but reviews summarise primary literature; they are not primary literature themselves, and both ultimately trace the diuretic claim back to this same 1967 paper and to the broader traditional record rather than to any additional experiment.

The paper itself predates the modern PubMed abstract era, so only its title, authors, journal and year are indexed — no abstract, no dose, no species-separation detail, no statistics. Its own title calls the work "preliminary," which is a rare moment of a primary source describing its own limitations accurately. The paper tested this plant alongside Tribulus terrestris, a separate herb with its own independent traditional and pharmacological identity; without the original text it is not possible to confirm here whether the two plants were tested as separate experimental arms or in combination, which is itself a reason for caution before treating this as clean single-species evidence.

Old, Weak and Positive — a Third Verdict

It is tempting to describe this claim as either "unsupported" or "supported by traditional research," and both of those roundings are wrong. There is a third category, and this claim sits in it precisely:

• Absent would mean no study was ever run. That is not the case here — something was tested, once, fifty-nine years ago.
• Refuted would mean an adequate study was run and found no effect. That is also not the case — the one paper that exists reports a positive result, as far as its title indicates.
• Old, weak and positive is the accurate description: a single, self-described-preliminary experiment, more than half a century old, never independently replicated by another group despite the plant's continued sale and use, with no abstract or methods available to assess its rigour today.

That is a genuinely different, more precise claim than "several studies show a diuretic effect" — and it is more useful to a reader than either "there's research on this" or "there's no research on this," because it tells you exactly how much weight one retrievable 1967 paper can bear, which is not very much, while still being honest that the traditional use did not originate from nothing.

The Furosemide Comparison That Could Not Be Confirmed

Secondary sources describing this plant sometimes state that its diuretic effect has been "benchmarked against furosemide," a standard loop-diuretic reference drug. A live, repeated search across all four species names combined with "furosemide" turns up zero primary papers reporting such a comparison for this species. It is entirely possible that such a comparison exists in a non-indexed source — an Indian pharmacy-college dissertation, a conference proceeding, or a journal not covered by PubMed — and this page cannot rule that out. What it can say is that a systematic, repeated, synonym-scoped live search did not surface one, which means a reader encountering the furosemide claim elsewhere should ask for the specific citation rather than accept it as an established fact. This page declines to repeat the comparison as though it were confirmed.

The Potassium Mechanism: Best Explanation and Main Hazard

The parent page already identifies the most parsimonious explanation for whatever diuretic effect this plant has: older pharmacognosy repeatedly notes that its ash is unusually rich in potassium salts, and a potassium load produces a modest natriuresis and diuresis through ordinary, well-understood renal handling — no exotic mechanism required. This deep-dive adds one point worth stating explicitly: the benefit and the hazard here are not two separate properties of the plant. They are the same property, described from two directions.

If potassium content is what drives the traditional diuretic effect, then the population most likely to notice that effect — people whose kidneys are already working harder to clear fluid and electrolytes — overlaps substantially with the population least able to safely handle an added potassium load. This is not a coincidental pairing of an unrelated benefit and an unrelated risk. It is one mechanism, and the caution below follows directly from it rather than from a separate, unconnected safety signal.

Kidney Stones: a Real Study, and What It Actually Shows

Unlike the diuretic claim itself, there is a genuine, specific, single-species animal study of this plant's effect on kidney-stone formation: Ingale, Thakurdesai and Vyawahare, Effect of Hygrophila spinosa in ethylene glycol induced nephrolithiasis in rats, Indian Journal of Pharmacology, 2012. This is worth reading precisely, because what it actually tested is narrower than "dissolves kidney stones" — the claim that circulates informally — and precision matters here.

The design: male rats were fed ethylene glycol to induce the standard laboratory model of calcium-oxalate stone formation, alongside a methanolic extract of the plant's aerial parts at 250 or 500 mg/kg. The extract was given throughout the stone-inducing protocol — a prevention design, not a dissolution design. The measured outcome: ethylene glycol produced the expected hyperoxaluria (excess urinary oxalate), increased urinary and kidney calcium, increased serum uric acid, and reduced urinary magnesium. In animals also given the extract, urinary and kidney oxalate and calcium were significantly lower, serum uric acid was lower, and urinary magnesium was higher — all findings consistent with reduced formation of the mineral deposits that become stones.

What this study supports: co-administered with a stone-forming challenge, an extract of this plant reduced the biochemical and tissue markers of new stone-forming mineral deposition in rats. What it does not support, and was not designed to test: whether an existing stone in a person's kidney or ureter would shrink, dissolve, or pass any more easily with this plant. "Dissolves kidney stones" — the claim actually made in casual marketing — is a dissolution claim about pre-formed stones. This is a prevention claim about new mineral deposition, tested only in a rat model, only alongside a specific chemical stone-inducing agent, and never in a human being. The two are not the same claim, and the existing literature only speaks to the second, narrower one.

A Second Renal Study: Cisplatin Protection

The same research group — Ingale, Thakurdesai and Vyawahare — published a second, related paper the following year: protection against cisplatin-induced nephrotoxicity in rats (Indian Journal of Pharmacology, 2013). Cisplatin is a chemotherapy drug whose dose-limiting toxicity is kidney damage, and this is a different model entirely from the stone-formation study above — a drug-toxicity protection model, closer in design logic to the liver-protection studies discussed on the Liver and Jaundice page than to the stone-prevention study immediately above it. Taken together, the two Ingale papers represent a small but coherent research programme from one Indian pharmacology group examining this plant's effects on renal chemistry from two different angles across two consecutive years — more depth than the diuretic claim itself has received from any single group, and worth noting as the more substantial of this plant's two kidney-related literatures.

How Diuresis and Stone Risk Are Actually Measured

It is worth naming the tools that exist for testing these claims properly, because doing so is the strongest available answer to "you can't run a trial on a traditional herb." Diuretic effect in humans is measured with metabolic-ward cumulative urine collection, timed electrolyte excretion, and comparison against a placebo and an active reference drug — standard, decades-old methodology used in every diuretic drug's approval trials. Kidney-stone risk is assessed with 24-hour urine collection for calcium, oxalate, citrate and uric acid; stone composition analysis when a stone is recovered; and imaging (CT or ultrasound) for stone burden and passage over time. None of these tools has ever been applied to this plant in a human being. The tools are not exotic or expensive by clinical-research standards; they are simply tools nobody has pointed at this specific plant.

Drug Interactions: Reasoned From Pharmacology, Not From a Study

A live search for any direct interaction study — this plant combined with lithium, with a named diuretic drug, or with any pharmacokinetic marker such as CYP enzymes or P-glycoprotein — returns zero results under any of the four species names. Every caution in this section is therefore reasoned from general, well-established pharmacology rather than from a study of this specific plant, and that distinction is stated here explicitly rather than left for the reader to assume.

• Lithium. Lithium has an unusually narrow safety margin, and its renal handling is tightly linked to sodium and fluid status: when the body is sodium- or fluid-depleted, the kidney reabsorbs more lithium along with more sodium, raising blood lithium levels toward toxicity. This is a well-documented mechanism behind why diuretic drugs and low-sodium states are a recognised lithium-toxicity risk in nephrology practice. A plant with any real diuretic or natriuretic action would be expected, on this mechanism alone, to carry the same risk — which is why the caution here does not require, and does not have, a study of this specific plant combined with lithium.
• ACE inhibitors, ARBs, and potassium-sparing diuretics. As discussed above, if this plant's diuretic action is substantially a potassium effect, then anyone already taking a drug that raises serum potassium — ACE inhibitors such as lisinopril or ramipril, ARBs such as losartan, or potassium-sparing diuretics such as spironolactone, eplerenone or amiloride — is stacking an uncounted potassium source onto an already-managed potassium budget. Hyperkalaemia is frequently silent until it produces a dangerous cardiac rhythm disturbance, which is what makes an uncounted contribution to a counted, monitored intake more dangerous than its small individual size would suggest.
• Standard diuretic drugs. Any real diuretic effect would be expected to add to, rather than replace, the fluid and electrolyte effects of furosemide, hydrochlorothiazide and similar prescription diuretics — increasing the risk of dehydration and low sodium (hyponatraemia), particularly in older adults.

What a UTI or an Active Stone Actually Needs

Two points from the parent page are worth restating here because they are the most clinically consequential facts on this entire page. A urinary tract infection needs antibiotics; left untreated, it can ascend to the kidneys as pyelonephritis and progress to sepsis, and a demulcent seed preparation that eases the burning sensation of a UTI without treating the infection removes the symptom that would otherwise prompt someone to seek care while the infection continues to climb. An obstructing kidney stone with fever, inability to pass urine, or uncontrolled pain is a urological emergency requiring imaging and, often, intervention — not something to wait out with a herbal diuretic on the theory that more urine flow will eventually clear it.

Human Evidence: Checked, and Absent

PubMed's own Clinical Trial and Randomised Controlled Trial publication-type filters, queried live across all four taxonomic names, return zero records for any urinary, diuretic or stone-related indication. No human dose-finding study, no human diuresis measurement, and no human stone-outcome trial exists for this plant under any name it has published under.

Back to Table of Contents

Key Research Papers

Every citation below is a PubMed search, never a bare identifier, so a mistyped or stale link cannot silently resolve to the wrong paper.

1. Kumari GS, Iyer GY. Preliminary studies on the diuretic effects of Hygrophila spinosa and Tribulus terrestris. Indian Journal of Medical Research, 1967. The sole retrievable primary diuretic study; no abstract indexed. Find on PubMed.
2. Ingale KG, Thakurdesai PA, Vyawahare NS. Effect of Hygrophila spinosa in ethylene glycol induced nephrolithiasis in rats. Indian Journal of Pharmacology, 2012. A prevention-of-deposition design; read in full above. Find on PubMed.
3. Ingale KG, Thakurdesai PA, Vyawahare NS. Protective effect of Hygrophila spinosa against cisplatin induced nephrotoxicity in rats. Indian Journal of Pharmacology, 2013. A drug-toxicity protection model, distinct from the stone-formation study above. Find on PubMed.
4. Kshirsagar AD, Ingale KG, Vyawahare NS, Thorve VS. Hygrophila spinosa: a comprehensive review. Pharmacognosy Reviews, 2010. Same lead research group as the two renal studies above. Find on PubMed.
5. Sethiya NK, Ahmed NM, Shekh RM, Kumar V. Ethnomedicinal, phytochemical and pharmacological updates on Hygrophila auriculata. Journal of Integrative Medicine, 2018. Find on PubMed.
6. Bennett WM. Drug interactions and consequences of sodium restriction. American Journal of Clinical Nutrition, 1997. The nephrology background explaining how a diuretic or sodium-depleted state raises blood lithium levels — general pharmacology, not specific to this plant. Find on PubMed.
7. General, not species-specific. Potassium-sparing diuretics, ACE inhibitors and the risk of hyperkalaemia. Search PubMed.
8. General, not species-specific. Furosemide mechanism of action at the loop of Henle, for context on what a genuine head-to-head comparator drug does. Search PubMed.
9. General. Nephrolithiasis diagnosis and management guidelines — how kidney stones are actually assessed in clinical practice. Search PubMed.
10. General. Urinary tract infection antibiotic treatment guidelines. Search PubMed.

Live PubMed Searches

• All names plus furosemide — run it yourself; this is the search that returns nothing
• Hygrophila spinosa and urolithiasis
• Herbal diuretics and lithium toxicity, generally

Back to Table of Contents

Connections

• All Herbs
• Marsh Barbel (Main Page)
• Marsh Barbel Benefits Hub
• Liver and Jaundice Claims
• Male Reproductive and Vrishya Claims
• Anti-Inflammatory and Blood-Sugar Research
• Uva Ursi — the urinary herb that does have some human data, and a clear duration cap
• Horsetail — the other classic herbal diuretic, with a comparable evidence problem
• Dandelion — another potassium-rich traditional diuretic, where the same caution applies
• Kidney Stones — what actually reduces recurrence
• Urinary Tract Infections — why these need antibiotics, not demulcents
• Potassium — the mineral behind both the diuretic mechanism and the main caution
• Kidney and Liver Conditions — the disease area this plant is traditionally aimed at

Back to Table of Contents